| Field |
Value |
| Gene Symbol |
MGEA5 |
| Full Name |
Meningioma Expressed Antigen 5 (N-acetylneuraminidase) |
| Chromosomal Location |
10q24.32 |
| Protein Product |
O-GlcNAcase (OGA) |
| EC Number |
3.2.1.96 |
| Alternative Names |
OGA, MGEA5, NCOAT (Nuclear Cytoplasmic O-GlcNAcase and Transcriptional coactivator) |
| UniProt ID |
Q9H3K2 |
| Protein Length |
917 amino acids |
| Molecular Weight |
~103 kDa |
MGEA5 encodes O-GlcNAcase (OGA), a glycoside hydrolase that catalyzes the removal of O-linked β-N-acetylglucosamine (O-GlcNAc) from serine and threonine residues on target proteins. This enzyme is a key component of the O-GlcNAcylation cycle, a dynamic post-translational modification (PTM) that regulates numerous cellular processes:
flowchart LR
A["Glucose"] -->|"Hexosamine<br/>Biosynthesis"| B["UDP-GlcNAc"]
B -->|"OGT adds<br/>GlcNAc"| C["Target Protein<br/>Tau, α-syn, APP"]
C -->|"MGEA5/OGA<br/>removes GlcNAc"| D["Native Protein"]
D --> B
style B fill:#e1f5fe,stroke:#333
style C fill:#e8f5e9,stroke:#333
style A fill:#fff3e0,stroke:#333
OGA employs a substrate-assisted retention mechanism distinct from classical hydrolytic enzymes:
- Substrate Binding: The enzyme recognizes the O-GlcNAcylated substrate through interactions with the sugar ring and aglycone moiety.
- Catalytic Nucleophile Attack: The catalytic aspartate performs nucleophilic attack on the anomeric carbon, forming a covalent enzyme-intermediate complex.
- Glycosyl Flip: The covalent intermediate undergoes a conformational change that facilitates the flip of the sugar.
- Hydrolysis: Water attacks the intermediate, releasing free GlcNAc and regenerating the enzyme.
The catalytic center contains two essential aspartate residues (Asp174 and Asp175) that coordinate the substrate and facilitate catalysis.
¶ Domain Structure
MGEA5/OGA contains two functional domains:
- N-terminal Domain: Contains the catalytic machinery and binds O-GlcNAcylated substrates. The active site pocket is highly conserved across species.
- C-terminal Domain: May function in substrate recognition and protein-protein interactions. Contains several proline-rich regions.
¶ Protein Structure and Catalysis
The three-dimensional structure of human OGA has been solved, revealing:
- A TIM-barrel fold in the catalytic domain
- A shallow substrate-binding groove
- Two critical catalytic aspartates in the active site
- Conformational flexibility that may allow accommodation of diverse substrates
OGA demonstrates:
- High specificity for O-GlcNAc over other glycosidic linkages
- Competitive inhibition by NAG-thiazoline compounds
- pH optimum around pH 5.5-6.0 in vitro
- Activity on both nuclear and cytoplasmic proteins
OGA is expressed throughout the brain with distinct patterns:
- Neurons: Highest expression in cortical pyramidal neurons, hippocampal CA1-CA3 neurons, and Purkinje cells in the cerebellum.
- Astrocytes: Moderate expression, particularly in white matter tracts.
- Microglia: Expression increases upon activation.
- Oligodendrocytes: Lower baseline expression, increases during myelination.
OGA activity is highest in:
- Cerebral cortex (particularly frontal and temporal lobes)
- Hippocampus (CA1 region most vulnerable in AD)
- Basal ganglia
- Brainstem motor nuclei
In neurodegenerative diseases, OGA expression is altered:
- Alzheimer's disease: Reduced OGA activity in the hippocampus and cortex, correlating with tau pathology severity.
- Parkinson's disease: Variable changes in OGA levels in the substantia nigra and striatum.
- Progressive supranuclear palsy: Increased OGA in affected brain regions, potentially as a compensatory response.
OGA regulates the O-GlcNAcylation of tau protein at multiple sites:
- Competition with phosphorylation: O-GlcNAcylation and phosphorylation compete for the same serine/threonine residues (Thr231, Ser396, Ser404).
- Protection against aggregation: O-GlcNAcylated tau shows reduced fibrillization in vitro.
- NFT correlation: Tau in neurofibrillary tangles has reduced O-GlcNAcylation compared to soluble tau.
OGA influences amyloid pathology through:
- APP processing: O-GlcNAcylation of APP at Thr576 reduces β-secretase cleavage.
- BACE1 modulation: O-GlcNAcylation of BACE1 decreases its activity.
- Amyloid-beta effects: Aβ exposure reduces global O-GlcNAcylation, creating a feed-forward cycle.
OGA inhibition improves synaptic plasticity and memory:
- Enhanced long-term potentiation (LTP) in hippocampal slices
- Improved performance on spatial memory tasks in mice
- Protection against excitotoxic neuronal death
Increasing tau O-GlcNAcylation through OGA inhibition represents a promising AD therapeutic strategy that:
- Directly targets tau pathology
- Complements amyloid-targeting approaches
- May protect synaptic function
OGA modulates α-synuclein pathology:
- O-GlcNAcylation of α-synuclein at Ser87 reduces aggregation propensity.
- O-GlcNAcylated α-synuclein shows altered membrane binding.
- Reduced aggregation correlates with decreased toxicity in cell models.
OGA function is particularly relevant to dopaminergic neuron survival:
- Metabolic stress reduces O-GlcNAcylation in these neurons.
- OGA inhibition protects against MPTP-induced toxicity.
- May modulate LRRK2 kinase activity through O-GlcNAcylation.
Microglial OGA regulates inflammatory responses:
- O-GlcNAcylation of IκB kinase (IKK) modulates NF-κB signaling.
- OGA inhibition reduces pro-inflammatory cytokine production.
- Potential for modulating neuroinflammation in PD.
Progressive supranuclear palsy shows particular sensitivity to OGA modulation:
- Elevated tau phosphorylation at multiple epitopes
- OGA inhibition reduces pathological phosphorylation
- Neurofibrillary tangles contain under-O-GlcNAcylated tau
OGA targeting may benefit CBS through:
- Tau pathology modification in cortical neurons
- Protection of GABAergic interneurons
- Modulation of astrocyte reactivity
Several OGA inhibitors have entered clinical development:
| Compound |
Company |
Phase |
Trial ID |
Status |
| FNP-223 (Etiglutide) |
Ferrer |
Phase 2 |
NCT04130095 |
Active |
| LY-3372689 (Zaniglusab) |
Eli Lilly |
Phase 2 |
NCT05063539 |
Recruiting |
| MK-8719 |
Merck |
Phase 1 |
NCT03055468 |
Completed |
- OGT (O-GlcNAc transferase): The counter-enzyme that adds O-GlcNAc. OGA and OGT function in a dynamic cycle.
- NAG (N-acetylglucosaminidase): Involved in the salvage pathway of GlcNAc.
Key neurodegeneration-relevant substrates:
- Tau: Multiple sites including Thr231, Ser396, Ser404
- α-Synuclein: Ser87, Thr72, Tyr133
- APP: Thr576
- BACE1: Multiple sites
- Synapsin I: Synaptic vesicle regulation
- MAPK kinases: Signaling pathway modulation
- P38 MAPK: Phosphorylation regulates OGA activity
- PP1/PP2A: Phosphatases that may dephosphorylate OGA
- 14-3-3 proteins: Bind and regulate OGA localization
OGA activity is linked to cellular metabolism:
- UDP-GlcNAc availability depends on glucose flux through the hexosamine biosynthesis pathway
- Nutrient status directly affects O-GlcNAcylation levels
- Diabetes risk variants in MGEA5 may alter this relationship
OGA regulates mitochondrial proteins:
- O-GlcNAcylation of respiratory chain complexes
- Modulation of ATP production
- Protection against oxidative stress
- Mechanism: Thiazoline-based OGA inhibitor
- Delivery: Oral administration
- Phase: Phase 2 for PSP
- Results: Reduced CSF tau in dose-escalation study
- Mechanism: NAG-thiazoline analog
- Delivery: Intravenous infusion
- Phase: Phase 2 for AD and PSP
- Rationale: Enhanced brain penetration
- Mechanism: Selective OGA inhibitor
- Delivery: Oral
- Phase: Phase 1 completed
- Status: No further development announced
OGA inhibition increases O-GlcNAcylation of tau and other proteins, which:
- Reduces phosphorylation at disease-relevant epitopes (Thr231, Ser396, Ser404)
- Decreases tau aggregation and NFT formation
- May protect against neuronal death
- Modulates synaptic protein function
¶ Challenges and Considerations
- Blood-brain barrier penetration: Critical for CNS efficacy
- Peripheral activity: May cause gastrointestinal side effects
- Long-term safety: Chronic OGA inhibition effects unknown
- Biomarker development: Need to monitor target engagement
- MGEA5 knockout: Embryonic lethal, demonstrating essential function
- Conditional knockout: Brain-specific deletion causes neurodegeneration
- Phenotype: Impaired O-GlcNAcylation, tau hyperphosphorylation
- hTau mice: OGA inhibition reduces tau pathology
- APP/PS1 mice: OGA inhibition improves memory
- α-synuclein models: Reduced aggregation with OGA inhibition
- Total tau: Decreases with effective OGA inhibition
- Phospho-tau: Reduced at target epitopes
- O-GlcNAcylated proteins: Potential direct biomarker
- Peripheral blood mononuclear cell O-GlcNAcylation: May correlate with CNS target engagement
- Platelet OGA activity: Potential pharmacodynamic marker
- PET tau ligands: May track treatment effects
- FDG-PET: Metabolic changes with treatment
- SNPs in MGEA5 associated with type 2 diabetes risk
- May influence OGA expression levels
- No direct link to neurodegeneration risk
- No known pathogenic mutations causing neurodegeneration
- Gene is considered essential
- Combination therapies: OGA inhibitors with amyloid-targeted agents
- Personalized medicine: Stratification based on OGA expression
- Delivery optimization: Improved brain penetration
- Biomarker development: Real-time target engagement monitoring
- What is the optimal level of OGA inhibition?
- Which patient populations will benefit most?
- Can OGA inhibition modify disease progression?
- What are long-term safety implications?